A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1/2a Clinical Trial to Evaluate the Pharmacokinetics/Pharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients
Latest Information Update: 09 Apr 2026
At a glance
- Drugs AD 303A (Primary)
- Indications Alopecia
- Focus Pharmacokinetics
- Sponsors Moogene Medi
Most Recent Events
- 09 Apr 2026 New trial record